Şen ÇakiroĞlu Gözde, Hİzmetlİ Sami, SİlİĞ Yavuz, KaradaĞ Ahmet, Hayta Emrullah, Özaltin Burcu, TaŞ Ayça, Zontul Cemile
Department of Physical Medicine and Rehabilitation, Niğde State Hospital, Niğde, Turkey.
Department of Physical Medicine and Rehabilitation, Cumhuriyet University Faculty of Medicine, Sivas, Turkey.
Arch Rheumatol. 2020 Feb 7;35(3):328-334. doi: 10.46497/ArchRheumatol.2020.7602. eCollection 2020 Sep.
This study aims to compare the beta-2 adrenergic receptor (ADRB2) gene polymorphisms of patients with fibromyalgia syndrome (FMS) with those of healthy control subjects, and to investigate the possible relationship between symptoms of FMS and polymorphisms of the ADRB2 gene.
The study included 170 females (mean age 47.8±10.3 years; range, 21 to 75 years) diagnosed with FMS according to the 2010 American College of Rheumatology criteria and 170 healthy females (mean age 47.2±8.8 years; range, 20 to 72 years) as the control group. Several clinical symptoms of the participants related to FMS were questioned and recorded. The visual analog scale (VAS) and Fibromyalgia Impact Questionnaire (FIQ) scores of the fibromyalgia group were recorded. In both groups, the ADRB2 (rs1042717) single-nucleotide polymorphism was detected by way of a real-time polymerase chain reaction. The wild-type (Guanine/Guanine), the mutant type (Adenine/Adenine) and heterozygous type (Adenine/Guanine) were detected. The sample power was calculated considering the minor allele frequency.
The comparison of the ADRB2 gene polymorphism between patients with FMS and the control subjects showed that the groups were similar in terms of ADBR2 gene polymorphism and genotype (p>0.05). There was no significant difference in terms of genotype when the ADRB2 gene polymorphisms in patients with FMS were compared in terms of clinical symptoms, VAS and FIQ scores (p>0.05).
Beta-2 adrenergic receptor (rs1042717) gene polymorphisms and genotype distribution are no different between patients with FMS and healthy individuals. ADRB2 gene polymorphisms in patients with FMS have no effect on clinical symptoms and VAS and FIQ scores. The results of the present study will light the way for future research into ADRB2 gene polymorphisms in the pathogenesis of FMS.
本研究旨在比较纤维肌痛综合征（FMS）患者与健康对照者的β-2肾上腺素能受体（ADRB2）基因多态性，并探讨FMS症状与ADRB2基因多态性之间的可能关系。
本研究纳入了170名根据2010年美国风湿病学会标准诊断为FMS的女性（平均年龄47.8±10.3岁；范围21至75岁）以及170名健康女性（平均年龄47.2±8.8岁；范围20至72岁）作为对照组。询问并记录了参与者与FMS相关的几种临床症状。记录了纤维肌痛组的视觉模拟量表（VAS）和纤维肌痛影响问卷（FIQ）得分。在两组中，通过实时聚合酶链反应检测ADRB2（rs1042717）单核苷酸多态性。检测到野生型（鸟嘌呤/鸟嘌呤）、突变型（腺嘌呤/腺嘌呤）和杂合型（腺嘌呤/鸟嘌呤）。考虑次要等位基因频率计算样本效能。
FMS患者与对照者之间ADRB2基因多态性的比较表明，两组在ADBR2基因多态性和基因型方面相似（p>0.05）。根据临床症状、VAS和FIQ得分比较FMS患者的ADRB2基因多态性时，基因型方面无显著差异（p>0.05）。
FMS患者与健康个体之间β-2肾上腺素能受体（rs1042717）基因多态性和基因型分布无差异。FMS患者的ADRB2基因多态性对临床症状以及VAS和FIQ得分无影响。本研究结果将为未来研究ADRB2基因多态性在FMS发病机制中的作用指明方向。
